BCP
ONC

Blackhawk Capital Partners’s BeOne Medicines Ltd ONC Stock Holding History

Blackhawk Capital Partners’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-310
Closed -$48K – 289
2018
Q2 		$48K Buy
310
+113
+57% +$20.2K 0.05% 168
2018
Q1 		$33K Buy
+197
New +$26.7K 0.03% 199

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Blackhawk Capital Partners's ONC Position: Q3 2018 in Review

Blackhawk Capital Partners sold out of BeOne Medicines Ltd (ONC) in Q3 2018, closing a stake of 310 shares — an estimated $48K sold.

Blackhawk Capital Partners first reported a position in ONC in Q1 2018 and held it in 2 quarters. The position peaked at $48K in Q2 2018. 144 funds tracked by Wall St. Rank hold ONC as of Q3 2018.

  • Blackhawk Capital Partners reported no remaining BeOne Medicines Ltd position as of Q3 2018 after selling out during the quarter.
  • Blackhawk Capital Partners sold 310 BeOne Medicines Ltd shares in Q3 2018, an estimated $48K.
  • Blackhawk Capital Partners first reported a position in BeOne Medicines Ltd in Q1 2018 and held it in 2 quarters.
  • Blackhawk Capital Partners's BeOne Medicines Ltd position peaked at $48K in Q2 2018.
  • 144 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2018.

Based on Blackhawk Capital Partners's 13F filing for Q3 2018, filed 13 Nov 2018.